Health Care — Alle selskaper
Eye.Ax
EYE.AX has a liquidity position characterized by a current ratio of 2.39, indicating the company has sufficient current assets to cover its current liabilities more than twice over. The company hol…
GlaxoSmithKline Pharmaceuticals Ltd
The company maintains a strong liquidity position, with a current ratio of 1.79 and cash and equivalents of INR 4.35 billion. Its debt-to-equity ratio is 0.01, indicating a conservative capital str…
Harvard Bioscience Inc
Harvard Bioscience operates with a market capitalization of $24.9 million and a price-to-book ratio of 1.81, indicating a moderate premium to its book value. The company's liquidity position is cha…
Vyome Holdings Inc
Vyome Holdings Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.00 and no long-term debt. The company maintains a strong liquidity p…
Immutep Ltd
Immutep operates with a highly liquid capital structure, as evidenced by a current ratio of 11.69, indicating strong short-term liquidity. The company holds cash and equivalents of AUD 17.26 millio…
Inogen Inc
Inogen operates with a cash-and-equivalents position of $103.7 million, representing 34.7% of total assets, and no long-term debt, resulting in a debt-to-equity ratio of 0.00. The company's liquidi…
Integrum AB
The company's capital structure is characterized by a low debt-to-equity ratio of 0.03, indicating a conservative leverage position. However, the liquidity risk is rated as medium, and the company…
Intuitive Surgical Inc
Intuitive Surgical maintains a strong capital structure with a current ratio of 5.15, indicating robust short-term liquidity. The company holds $2.56 billion in cash and equivalents, with no long-t…
Genomma Lab Internacional SAB de CV
Genomma Lab maintains a leveraged capital structure with total liabilities of 12.72 billion MXN against total equity of 11.11 billion MXN, resulting in a debt-to-equity ratio of 0.69. The company h…
MBX Biosciences Inc
MBX Biosciences has a strong liquidity position, with a current ratio of 24.62 and $75.29 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company is…
NovaBridge Biosciences
InspireMD Inc
InspireMD Inc has a market capitalization of $53.46 million and a price-to-book ratio of 0.97, indicating that the company is trading at a slight discount to its book value. The company's liquidity…
OKYO Pharma Ltd
OKYO Pharma operates with a negative equity position of £-5.55 million and a current ratio of 0.4, indicating significant liquidity constraints. The company's market capitalization stands at £84.49…
Omda AS
Omda AS has a high liquidity risk, as indicated by a current ratio of 0.73, which is below 1, suggesting that the company may struggle to meet its short-term obligations with its current assets. Th…
Perrigo Company PLC
Perrigo's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. The company's liquidity position is mixed, with $531.6 million in c…
Plus Therapeutics Inc
The company's capital structure is characterized by a negative equity position of $4.84 million and a debt-to-equity ratio of -0.74, indicating a leveraged position with liabilities exceeding asset…
Pelthos Therapeutics Inc
Pelthos Therapeutics Inc has a market capitalization of $92.91 million and a price-to-book ratio of 2.39, indicating that the market values the company at a premium to its book value. The company's…
Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals has a market capitalization of $10.48 million and a price-to-book ratio of 1.15, indicating that the market values the company slightly above its book value. The company's liq…
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc maintains a strong liquidity position, with a current ratio of 5.44 and cash and equivalents of $1.92 billion. The company's debt-to-equity ratio is 0.1, indicating a…
Richards Group Inc
Richards Group Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.48, indicating a relatively low reliance on debt financing. The company's liquidity position is charac…
Riverstone Holdings Ltd
Riverstone Holdings Ltd maintains a strong liquidity position, with a current ratio of 9.23 and no long-term debt, indicating a robust balance sheet and minimal leverage. The company holds MYR 294.…
Revolution Medicines Inc
Revolution Medicines operates with a strong liquidity position, as evidenced by its current ratio of 18.45 and cash and equivalents of $288.43 million. The company has no long-term debt, and its de…
Sanofi India Ltd
Sanofi India Ltd maintains a strong liquidity position, with a current ratio of 1.63 and cash and equivalents amounting to INR 2.3 billion. The company's liquidity risk is assessed as low, supporte…
Scancell Holdings PLC
Scancell's capital structure is characterized by a negative equity position of £3.84 million and a debt-to-equity ratio of -4.24, indicating a leveraged position with liabilities exceeding assets.…
Senzime AB (publ)
Senzime operates with a strong equity base of 304.5 million SEK and a low debt-to-equity ratio of 0.05, indicating a conservative capital structure. The company's liquidity position is characterize…
Sight Sciences Inc
Sight Sciences maintains a strong liquidity position with $91.97 million in cash and equivalents, which is significantly higher than its total liabilities of $51.36 million, resulting in a current…
Square Pharmaceuticals PLC
Square Pharmaceuticals maintains a robust capital structure, with a debt-to-equity ratio of 0.01, indicating minimal leverage and strong equity backing. The company's liquidity position is characte…
Strides Pharma Science Ltd
Strides Pharma Science Ltd has a debt-to-equity ratio of 0.74, indicating a moderate level of leverage, and a current ratio of 1.2, suggesting limited short-term liquidity cushion. The company's fr…
Sensus Healthcare Inc
Sensus Healthcare Inc maintains a strong liquidity position, with a current ratio of 9.85 and $14.73 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The…
Surrozen Inc
Surrozen operates with a negative equity position of -$187.76 million and a cash balance of $89.25 million, indicating a high reliance on liquidity reserves to fund operations. The company's liquid…
TELA Bio Inc
TEL Bio Inc operates with a high debt-to-equity ratio of 8.82, indicating a capital structure heavily reliant on debt financing. The company holds $50.85 million in cash and equivalents, but this i…
Alpha Teknova Inc
Alpha Teknova Inc operates with a liquidity position that appears robust, as evidenced by a current ratio of 4.76 and cash and equivalents of $18.596 million. The company's price-to-book ratio of 2…
Transmedics Group Inc
Transmedics Group Inc maintains a strong liquidity position with $488.37 million in cash and equivalents, which is significantly higher than its $512.39 million in long-term debt, resulting in a ne…
Tango Therapeutics Inc
Tango Therapeutics operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company maintains a strong liquidity position…
Traws Pharma Inc
Traws Pharma Inc has a market capitalization of $22.57 million and a price-to-earnings ratio of 2.46, indicating a relatively low valuation compared to earnings. The company's liquidity position is…
Transgene SA
Transgene operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 0.02, indicating minimal reliance on debt financing. However, the company's liquidity positio…
Upstream Bio Inc
Upstream Bio Inc has a strong liquidity position, with a current ratio of 26.15, indicating that the company holds significantly more current assets than current liabilities. The company's cash and…
Vext Science Inc
Vext Science Inc has a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's current ratio of 1.76 suggests…
Vveo3.Sa
The company's capital structure is characterized by a high debt-to-equity ratio of 2.0, indicating a significant reliance on debt financing. The liquidity position is moderate, with a current ratio…
Jilin Aodong Pharmaceutical Group Co Ltd
Jilin Aodong Pharmaceutical Group Co Ltd maintains a strong capital structure with a low debt-to-equity ratio of 0.08, indicating minimal reliance on debt financing. The company's liquidity positio…
Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 1.73, indicating the company can cover its short-term liabilities with its short-term assets. T…
Double Medical Technology Inc
Double Medical Technology Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.13, significantly below the industry median of 0.45, indicating a low reliance on debt fina…
042520.Kq
The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
1521.Hk
The company maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.37, indicating a moderate reliance on debt financing. Its liquidity position is characterized by…
1784.Two
1784.TWO maintains a relatively strong liquidity position, with a current ratio of 4.62, indicating the company can cover its short-term liabilities more than four times over with its current asset…
Jetema Co Ltd
Jetema maintains a debt-to-equity ratio of 1.67, indicating a capital structure that is moderately leveraged relative to equity. The company holds 31.0 billion KRW in cash and equivalents, but this…
Shin Nippon Biomedical Laboratories Ltd
The company's capital structure is characterized by a debt-to-equity ratio of 1.01, indicating a balanced mix of debt and equity financing. It holds JPY 10,964,538,000 in cash and equivalents, but…
293480.Ks
The company maintains a relatively strong liquidity position, with a current ratio of 1.84, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its fre…
Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical maintains a strong capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is c…
Medtide Inc
Medtide Inc maintains a strong liquidity position, as evidenced by a current ratio of 6.4, indicating the company has sufficient current assets to cover its current liabilities multiple times over.…
NextBioMedical Co Ltd
NextBioMedical operates with a highly leveraged capital structure, as evidenced by its total liabilities of 3.56 trillion KRW and total equity of -572.71 billion KRW, resulting in a negative debt-t…
Santen Pharmaceutical Co Ltd
Santen maintains a strong liquidity position with a current ratio of 2.58 and cash and equivalents of ¥92.997 billion, which provides a buffer against short-term obligations. The company's debt-to-…
4881.T
The company maintains a strong liquidity position, with a current ratio of 3.74, indicating that it has sufficient current assets to cover its current liabilities. The company's price-to-book ratio…
Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as…
Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical maintains a strong liquidity position, with a current ratio of 1.92, indicating the company can cover its short-term liabilities nearly twice over. However, the compan…
603087.Ss
The company maintains a strong liquidity position, with a current ratio of 6.72, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 77.43 million CNY, wh…
7762.Two
The company maintains a strong capital structure, with a debt-to-equity ratio of 0.09, indicating a low reliance on debt financing. However, its liquidity position is assessed as medium, with a cur…
Aardvark Therapeutics Inc
Aardvark Therapeutics Inc maintains a strong liquidity position, with a current ratio of 32.67, indicating a high ability to meet short-term obligations. The company has no long-term debt and holds…
Aawhu.Cd
AAWHU.CD's capital structure is marked by a negative total equity of -$47.44 million, indicating a significant debt burden relative to its equity base. The company's liquidity position is character…
Abot.Ns
ABOT.NS maintains a strong liquidity position, with a current ratio of 3.39 and a debt-to-equity ratio of 0.05, indicating a low reliance on debt financing and a robust balance sheet. The company's…
ADC Therapeutics SA
ADC Therapeutics operates with a capital structure that is highly leveraged, as evidenced by its total liabilities of $508.98 million and total equity of -$185.83 million, resulting in a debt-to-eq…
Amlx.O
The company maintains a conservative capital structure with zero debt-to-equity and a strong liquidity position, holding $226.7 million in cash and equivalents against total liabilities of $27.4 mi…
Annovis Bio Inc
Annovis Bio Inc has a market capitalization of $73.8 million and a price-to-book ratio of 4.38, indicating a premium valuation relative to its book value. The company holds $19.5 million in cash an…
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc has a negative net equity of -$98.31 million, indicating a significant equity deficit, and a current ratio of 0.59, suggesting limited short-term liquidity. The company's…
Biohit Oyj
BIOBV.HE maintains a strong liquidity position, with a current ratio of 2.56, indicating the company can cover its short-term liabilities more than twice over. The company's liquidity_fpt score is…
Bionano Genomics Inc
Bionano Genomics operates with a highly leveraged capital structure, evidenced by a price-to-book ratio of 0.29 and a tangible book ratio of 0.29, both significantly below the industry median. The…
Cellbxhealth PLC
CancerLinX has a highly leveraged capital structure, with a price-to-book ratio of 106.58 and a price-to-tangible-book ratio of 106.58, indicating a significant premium over its book value. The com…
Clinical Laserthermia Systems AB
Clinical Laserthermia Systems AB operates with a current liquidity position that is medium risk, as indicated by a negative net cash position after accounting for total debt. The company's liquidit…
Cnvi.V
The company's capital structure is highly leveraged, with total liabilities of CAD 30.5 million and total equity of CAD -18.0 million, resulting in a debt-to-equity ratio of -1.1. Despite holding C…
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc has a market capitalization of $73.72 million and a price-to-book ratio of 2.8, indicating a premium valuation relative to its book value. The company holds $17.34 mi…
C Rad AB
C Rad AB maintains a strong liquidity position with a current ratio of 2.84, indicating the company can cover its short-term obligations more than two and a half times over. The company's debt-to-e…
Curas.Te
The company's capital structure is characterized by a debt-to-equity ratio of 1.4, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current rat…
Cyc.Ax
Cyclica's capital structure shows a debt-to-equity ratio of 0.29, indicating a relatively low level of leverage compared to the industry median. The company's liquidity position is characterized as…
Dyadic International Inc
Dyadic International Inc has a market capitalization of $28.6 million and a price-to-book ratio of 23.2, indicating a high valuation relative to its book value. The company's liquidity position is…
Edesa Biotech Inc
Edesa Biotech maintains a strong liquidity position, with cash and equivalents of $10.79 million, representing 79.7% of total assets, and a current ratio of 10.67, indicating a robust ability to me…
Greenwich Lifesciences Inc
Greenwich Lifesciences Inc has a market capitalization of $359.8 million and a price-to-book ratio of 53.7, indicating a high valuation relative to its book value. The company has no long-term debt…
Grfs.O
Grifols maintains a capital structure with a debt-to-equity ratio of 1.83, indicating a relatively high leverage position compared to industry norms. The company's liquidity is assessed as medium,…
Hls Therapeutics Inc.
HLS has a market capitalization of $142.3 million and a price-to-book ratio of 2.31, indicating that the market values the company at a premium to its book value. The company's liquidity position i…
Henry Schein Inc
Henry Schein Inc has a market price of $72.99 and a market cap of $8.37 billion, with a price-to-earnings ratio of 80.53 and a price-to-book ratio of 2.38. The company's liquidity is characterized…
MindWalk Holdings Corp
MindWalk Holdings Corp has a market capitalization of CAD 56.05 million and a price-to-book ratio of 2.37, indicating a premium valuation relative to its book value. The company's liquidity positio…
IN8bio Inc
IN8bio operates with a market capitalization of $15.66 million and a price-to-book ratio of 1.15, indicating that the market values the company slightly above its book value. The company's liquidit…
Iolc.Ns
The company maintains a strong liquidity position with a current ratio of 1.89, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its free cash flow…
Standard BioTools Inc
Standard BioTools maintains a conservative capital structure with $120.9 million in cash and equivalents, representing 21.3% of total assets, and no long-term debt. The company's liquidity position…
Lisata Therapeutics Inc
Lisata Therapeutics Inc maintains a strong liquidity position, with a current ratio of 8.92, indicating that the company has significantly more current assets than current liabilities. The company'…
Marinomed Biotech AG
Marinomed Biotech AG has a negative equity position of EUR -11.84 million and a debt-to-equity ratio of -1.84, indicating a leveraged capital structure with liabilities exceeding assets. The compan…
Seres Therapeutics Inc
Seres Therapeutics operates with a negative equity position of -$59.7 million and a cash and equivalents balance of $111.2 million, indicating a liquidity position that is sufficient to cover short…
Medicus Pharma Ltd
Medicus Pharma operates with a total equity of $6.45 million and a total asset base of $8.78 million, indicating a relatively strong capital structure. The company's debt-to-equity ratio is 0.06, s…
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp operates with a strong liquidity position, as evidenced by its current ratio of 6.66, indicating that the company has significantly more current assets than current liab…
Natac Natural Ingredients S.A.
NAT.MC has a liquidity risk profile that is characterized by a current ratio of 0.58, indicating that the company's current liabilities exceed its current assets, which could pose challenges in mee…
Oncolytics Biotech Inc
Oncolytics Biotech Inc has a capital structure characterized by a low debt-to-equity ratio of 0.05, indicating minimal reliance on debt financing, and a strong liquidity position with a current rat…
Onesource Specialty Pharma Ltd
Onesource Specialty Pharma Ltd has a debt-to-equity ratio of 0.16, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is assessed as medi…
Puma Biotechnology Inc
Puma Biotechnology Inc maintains a strong liquidity position, with a current ratio of 2.0 and a free cash flow of $41.98 million, indicating robust short-term financial flexibility. The company's p…
Phar.Ca
Pharos maintains a capital structure with a debt-to-equity ratio of 1.41, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1…
Poly Medicure Ltd
Poly Medicure Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized by a…
Recce Pharmaceuticals Ltd
RCE.AX exhibits a highly leveraged capital structure, with total liabilities of AUD 15.47 million and total equity of -AUD 3.05 million, resulting in a debt-to-equity ratio of -3.53. The company's…
AVITA Medical Inc
AVITA Medical operates with a market capitalization of $134.19 million and a price-to-book ratio of 4.12, indicating a premium valuation relative to its book value. The company's liquidity position…
Rubicon Organics Inc
Rubicon Organics has a liquidity position that is marginally stable, with a current ratio of 1.57, indicating that it can cover its short-term liabilities with its short-term assets. However, the c…
Ryvu Therapeutics SA
Ryvu Therapeutics operates with a capital structure that includes a debt-to-equity ratio of 1.78, indicating a relatively high level of leverage. The company's liquidity position is characterized b…
Sartorius AG
Sartorius maintains a capital structure with a debt-to-equity ratio of 1.58, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio o…
SciBase Holding AB (publ)
SciBase Holding AB (publ) has a strong liquidity position, with cash and equivalents amounting to 43.27 million SEK, representing 58.6% of total assets. The company has no long-term debt, and its d…
Skye Bioscience Inc
Skye Bioscience Inc maintains a strong liquidity position, with cash and equivalents amounting to $83.34 million, significantly exceeding its total liabilities of $15.95 million, resulting in a cur…
Som.Ax
SOM.AX has a current ratio of 1.51, indicating moderate liquidity, but its free cash flow is negative at -1.69 million AUD, suggesting cash flow constraints. The company's debt-to-equity ratio is 0…
Stereotaxis Inc
Stereotaxis operates with a cash balance of $13.42 million and no long-term debt, resulting in a debt-to-equity ratio of 0.00. The company's liquidity position is reflected in a current ratio of 1.…
SyntheticMR AB (publ)
SYNTH.TE has a current ratio of 2.09, indicating a moderate level of liquidity, but its operating cash flow is negative at -5.47 million SEK, suggesting ongoing cash flow challenges. The company's…
UFP Technologies Inc
UFP Technologies Inc has a market capitalization of $1.75 billion and trades at a price-to-earnings ratio of 25.61, which is above the industry median of 18.2. The company's price-to-book ratio of…
Unite de Fabrication de Medicaments SA
The company's capital structure is characterized by a high level of long-term debt, with 45,092,300 TND in long-term obligations, which exceeds its revenue of 32,757,760 TND. This suggests a potent…
United Therapeutics Corp
United Therapeutics Corp maintains a strong liquidity position with $1.56 billion in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 6.…
Vfy.Ax
The company's capital structure is characterized by a high price-to-book ratio of 5.75 and a price-to-tangible-book ratio of 5.75, indicating that the market is valuing the company's equity at a pr…
Exicure Inc
Exicure operates with a market capitalization of $20.27 million and a price-to-book ratio of 9.18, indicating a premium valuation relative to its book value. The company has no long-term debt and a…
Meinian Onehealth Healthcare Holdings Co Ltd
Meinian Onehealth Healthcare Holdings Co Ltd has a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing, while its current ratio of 0.84 suggests potential short-term liqu…
Hanall Biopharma Co Ltd
Hanall Biopharma maintains a strong liquidity position with a current ratio of 3.14, indicating the company can cover its short-term liabilities more than three times over. The company holds KRW 17…
Whanin Pharm Co Ltd
Whanin Pharm Co Ltd maintains a strong liquidity position with a current ratio of 4.04, indicating the company can easily cover its short-term liabilities with its current assets. The company's cas…
Dongkook Pharmaceutical Co Ltd
Dongkook Pharmaceutical maintains a strong liquidity position, with a current ratio of 2.11 and free cash flow of 50,189,569,340 KRW, indicating the company has sufficient short-term assets to cove…
Vieworks Co Ltd
Vieworks maintains a conservative capital structure with a debt-to-equity ratio of 0.28, well below the industry median of 0.45, and a current ratio of 1.98, indicating strong short-term liquidity.…
Interojo Co Ltd
Interojo maintains a conservative capital structure with a debt-to-equity ratio of 0.27, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by…
AK Medical Holdings Ltd
The company maintains a strong liquidity position, with a current ratio of 4.1, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its net cash positi…
197a.T
197A.T maintains a liquidity position with a current ratio of 1.62, indicating the company can cover its short-term liabilities with its short-term assets. However, the company's free cash flow is…
DongBang Medical Co Ltd
DongBang Medical has a strong liquidity position, as evidenced by its operating cash flow of KRW 4,006,579,940 and free cash flow of KRW 3,023,619,220. The company's capital structure is supported…
Lepu Medical Technology (Beijing) Co Ltd
Lepu Medical Technology maintains a relatively strong liquidity position, with a current ratio of 2.74, indicating that it has more than double the current assets to cover its current liabilities.…
China Resources Boya Bio pharmaceutical Group Co Ltd
The company maintains a strong liquidity position, with a current ratio of 13.08, indicating a high ability to meet short-term obligations. However, the risk assessment notes that net cash is negat…
B-SOFT Co Ltd
B-SOFT's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. However, the company's liquidity is rated as medium, and its free cash…
Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co Ltd maintains a relatively strong liquidity position, with a market capitalization of CNY 2.94 billion and an enterprise value to revenue (EV/Revenue) ratio of 4.3…
Lunit Inc
Lunit Inc has a price-to-book ratio of 4.84, indicating that the market values the company at nearly five times its book value. The company's liquidity position is weak, with a current ratio of 0.2…
6185.Hk
The company's capital structure is characterized by a debt-to-equity ratio of 0.26, indicating a relatively low level of leverage. The liquidity position is assessed as medium, with a current ratio…
Abionyx Pharma
ABNX.PA has a market price of 3.475 EUR and a market capitalization of 122,643,348.75 EUR, indicating a relatively small market presence. The company's price-to-book ratio is 27.18, which is signif…
AC Immune SA
AC Immune operates with a market capitalization of CHF 307.36 million and a price-to-book ratio of 6.85, indicating a premium valuation relative to its book value. The company holds CHF 26.80 milli…
Adrg.Ns
ADRG.NS has a debt-to-equity ratio of 0.45, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is characterized as m…
Alector Inc
Alector maintains a strong liquidity position with $65.8 million in cash and equivalents, which is 25.8% of total assets, and a current ratio of 3.83, indicating the company can cover its short-ter…
Assertio Holdings Inc
Assertio's capital structure shows a market cap of $150.5 million with a price-to-book ratio of 1.6, indicating a moderate premium to its book value. The company holds $10.2 million in cash and equ…
Atrys Health, S.A.
Atryu's capital structure is characterized by a debt-to-equity ratio of 1.7, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a curr…
Arcticzymes Technologies ASA
Arcticzymes Technologies ASA maintains a strong liquidity position, with a current ratio of 16.39 and cash and equivalents amounting to NOK 187.78 million, which significantly exceeds its total lia…
Bioretec Oy
BRETEC.HE has a market price of 0.0226 EUR and a market capitalization of 30,324,362.76 EUR, with a price-to-book ratio of 3.11 and a price-to-tangible-book ratio of 3.11. The company's liquidity p…
Carlsmed Inc
Carlsmed Inc has a strong liquidity position, with cash and equivalents amounting to $85.79 million, which is significantly higher than its total liabilities of $31.25 million, resulting in a curre…
CDT Equity Inc
CDT Equity Inc has a negative equity position of -$3.1 million and a debt-to-equity ratio of -0.32, indicating a leveraged capital structure with liabilities exceeding assets. The company's liquidi…
Celc.O
CELC.O has a market capitalization of $6.74 billion and a price-to-book ratio of 67.03, indicating a high valuation relative to its book value. The company's liquidity position is characterized by…
Clnp.Wa
The company's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. However, the company reported negative free cash flow of -63.395…
Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd operates with a current market capitalization of $12.24 million and a price-to-book ratio of 0.92, indicating that the company is trading at a discount relative to its boo…
Coya Therapeutics Inc
Coya Therapeutics has a strong liquidity position, with a current ratio of 8.5 and cash and equivalents amounting to $46.8 million, which significantly exceeds its total liabilities of $6.9 million…
China Pharma Holdings Inc
China Pharma Holdings Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds total assets of $30.99 million against total liabi…
Champions Oncology Inc
Champions Oncology maintains a liquidity position of $9.79 million in cash and equivalents, representing 30.3% of total assets, while total liabilities of $28.57 million are significantly higher th…
Eureka Group Holdings Ltd
Eureka Group Holdings Ltd maintains a market capitalization of approximately AUD 248.8 million, with a price-to-earnings ratio of 12.4 and a price-to-book ratio of 1.04. The company's liquidity pos…
Elicera Therapeutics AB
Elicera Therapeutics AB maintains a strong liquidity position, with a current ratio of 4.23, indicating that the company has sufficient current assets to cover its current liabilities multiple time…
Evommune Inc
Evommune Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $44.1 million in cash and equivalents against total liabilities…
Femasys Inc
Femasys operates with a market capitalization of $27.8 million and a price-to-book ratio of 4.74, indicating a premium valuation relative to its book value. The company's liquidity position is char…
Foghorn Therapeutics Inc
Foghorn Therapeutics operates with a negative equity position of -$108.5 million and a cash balance of $80.9 million, indicating a liquidity position that is primarily asset-backed. The company's l…
Fluoguide AS
Fluoguide's capital structure is characterized by a debt-to-equity ratio of 1.81, indicating a relatively high leverage position. The company's liquidity is assessed as medium, with a current ratio…
Gfcm.Bk
GFCM.BK maintains a strong liquidity position, with a current ratio of 2.77, indicating the company can cover its short-term liabilities more than two and a half times over with its current assets.…
Herantis Pharma Oyj
HRTIS.HE exhibits a capital structure marked by significant leverage and negative equity. The company's debt-to-equity ratio is -2.04, indicating that liabilities exceed equity by a wide margin. Li…
TuHURA Biosciences Inc
TuHURA Biosciences Inc operates with a high price-to-book ratio of 7.15, indicating that the market is valuing the company significantly above its book value. The company's liquidity position is we…
Hyph.Si
HyPh maintains a strong liquidity position, with a current ratio of 2.03 and cash and equivalents amounting to SGD 26.83 million, which is a significant portion of its total assets of SGD 123.60 mi…